8-KOther Events

ABBOTT LABORATORIES 8-K Report, Corporate Update (Jul 7, 2017)

Filed July 7, 2017For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on July 7, 2017, to announce a key leadership change within its Medical Devices segment. Michael Rousseau, President of the Cardiovascular and Neuromodulation business, is departing the company following the completion of his planned transition period. This move comes as Abbott continues to integrate St. Jude Medical, Inc., which it acquired in January 2017. Investors should note that this is a planned departure and follows the successful integration of the acquired entity.

Key Highlights

  • 1Michael Rousseau, President of Cardiovascular and Neuromodulation, is leaving Abbott.
  • 2Rousseau's departure is effective July 7, 2017, after completing his transition period.
  • 3The departure is related to the ongoing integration of St. Jude Medical, Inc.
  • 4Robert Ford, Executive Vice President of Medical Devices, will assume leadership of the Cardiovascular and Neuromodulation business.
  • 5Ford's responsibilities will now encompass Vascular, Structural Heart, and Diabetes Care businesses in addition to the newly acquired businesses.
  • 6This change indicates a consolidation of leadership within Abbott's key medical device divisions.

Frequently Asked Questions

Michael Rousseau is leaving Abbott Laboratories as part of a planned transition period that has now been completed, following the integration of St. Jude Medical, Inc.

The impact is expected to be minimal as it's a planned departure. Robert Ford, the Executive Vice President of Medical Devices, will assume leadership of the Cardiovascular and Neuromodulation business, consolidating leadership for key medical device segments.

The filing states that Mr. Rousseau is leaving after his planned transition period is complete and that the integration of St. Jude Medical is proceeding, suggesting this is a planned organizational change rather than a performance-related issue.

Robert Ford will now lead the Cardiovascular and Neuromodulation business in addition to his existing responsibilities for the Vascular, Structural Heart, and Diabetes Care businesses, effectively overseeing a significant portion of Abbott's medical device portfolio.